Skip to content
Review

Abstract 15396: Comparative Efficacy and Safety of Apixaban versus Rivaroxaban in Obese Adults with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis

Nov 2026 · Circulation · Vol 154 · 0 citations

TL;DR

In obese or morbidly obese adults with NVAF, apixaban was associated with lower systemic embolization, myocardial infarction, gastrointestinal hemorrhage, and major bleeding than rivaroxaban, with no significant differences in ischemic stroke, intracranial bleeding, hemorrhagic stroke, or mortality.

Abstract

Introduction/Background: Nonvalvular atrial fibrillation (NVAF) is associated with obesity, and this could impact direct oral anticoagulant exposure and outcomes. This meta-analysis aims to find available evidence that compares apixaban with rivaroxaban in obese adults to treat NVAF. Research Question: Is apixaban superior to rivaroxaban in obese or morbidly obese adults with NVAF in terms of the thromboembolic and safety outcomes? Methods: PubMed, Scopus, Embase, Cochrane, and ClinicalTrials.gov were searched from inception to May 2026. Outcomes were systemic embolization, ischemic stroke, myocardial infarction, intracranial bleeding, hemorrhagic stroke, gastrointestinal hemorrhage, major bleeding, and all-cause mortality. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using Mantel-Haenszel random-effects models. Analyses were conducted using Revman 5.4.0. I 2 was used to assess heterogeneity, and GRADE was used to assess certainty of evidence. Results: Five comparative studies provided data (61,849 participants in total with an age ranging from 62.2±12.0 to 77.7±14.4 years). Statistically significant findings favored apixaban for systemic embolization (RR, 0.80; 95% CI, 0.65-0.99; p=0.04), myocardial infarction (RR, 0.58; 95% CI, 0.38-0.87; p=0.009), gastrointestinal hemorrhage (RR, 0.56; 95% CI, 0.35-0.89; p=0.01), and any major bleeding/major bleeding (RR, 0.58; 95% CI, 0.43-0.80; p=0.0009). The heterogeneity of myocardial infarction, gastrointestinal hemorrhage, and major bleeding was low, moderate, and substantial, respectively (I 2 =0%, I 2 =81%, and I 2 =61%). Statistically non-significant outcomes included ischemic stroke (RR, 0.88; 95% CI, 0.71-1.08; p=0.21), intracranial bleeding/hemorrhage (RR, 0.78; 95% CI, 0.52-1.15; p=0.21), hemorrhagic stroke (RR, 0.73; 95% CI, 0.47-1.15; p=0.17), and all-cause mortality (RR, 1.28; 95% CI, 0.89-1.85; p=0.18). Conclusion: In obese or morbidly obese adults with NVAF, apixaban was associated with lower systemic embolization, myocardial infarction, gastrointestinal hemorrhage, and major bleeding than rivaroxaban, with no significant differences in ischemic stroke, intracranial bleeding, hemorrhagic stroke, or mortality. Overall, apixaban may offer a more favorable effectiveness-safety profile, though findings should be interpreted cautiously given observational evidence and heterogeneity in bleeding outcomes.

View source

Similar papers

Review Nov 2026

Abstract 11720: Efficacy and Safety of Apixaban versus Rivaroxaban in Acute Venous Thromboembolism: A Systematic Review and Meta-Analysis

Introduction: Apixaban and rivaroxaban are commonly used direct oral factor Xa inhibitors for acute venous thromboembolism (VTE), but uncertainty remains about their comparative effectiveness and bleeding risk across general and cancer-associated VTE populations. Research Question: We evaluated whether apixaba...

Shaheer Bin Shafiq, A. Uddin, Muhammad Hassan et al. · 0 citations
Nov 2026

Abstract 14366: Not All Factor Xa Inhibitors Are Equal: Apixaban a Better Choice Than Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients: Evidence from a Meta-Analysis

Introduction: Behind every atrial fibrillation diagnosis lies a fivefold increased stroke risk, leading to inclusion of anticoagulant therapy. Transition from Vitamin K antagonists to Direct Oral Anti Coagulants (DOACs) has revolutionized anticoagulation in non-valvular atrial fibrillation, increasing compliance and...

Venkata Sai Abhilash Meda, Sreejith Vijayakumar, Manogna Pendyala · 0 citations
Review Nov 2026

Abstract 18882: Efficacy and Safety of Rivaroxaban in Patients with Peripheral Artery Disease: A GRADE-Assessed Systematic Review and Meta-Analysis

Background: Peripheral artery disease (PAD) is a progressive atherosclerotic condition associated with high cardiovascular and limb-related morbidity. Despite guideline-recommended antiplatelet therapy, patients with PAD remain at substantial residual risk of ischemic and limb events. Rivaroxaban, a direct Factor Xa...

M. Shahzaib, Muhammad Roshaan, Anza Muhammad et al. · 0 citations
Review Nov 2026

Abstract 13895: Comparison of Left Atrial Appendage Closure Devices with Oral Anticoagulation Therapy on Clinical Outcomes in Patients with Atrial Fibrillation: A Reconstructed Individual-Patient Data Meta-Analysis

Background: Oral anticoagulation (OAC) remains the cornerstone of stroke prevention in atrial fibrillation (AF), but its use is limited by bleeding risk. Left atrial appendage occlusion (LAAO) devices offer a nonpharmacological alternative; however, recent randomized trials have reported inconsistent efficacy compar...

Z. Bashir, M. Abdul Rehman, M. Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.